According to Gilead Sciences’ President and COO John Milligan, around 17,000 HCV patients were treated in France last year under a temporary utilization program. Sovaldi has come under fire for its high price tag. However, the company is negotiating price cuts in Europe with the expectation that patient volume increases will be dramatic.
The company is also expecting quick approvals for its newer combination pill, Harvoni, which combines Sovaldi with another Gilead anti-viral medication, according to the report.
More articles on GI/endoscopy:
GI physician leader to know: Dr. William Chey of University of Michigan Health System
Cantel Medical’s short interest drops by 4.5%: 4 key points
CCFA, AGA & Janssen Biotech create new grant program for epigenetic research in IBD
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.